文献速递心力衰竭与心肌病

社区疑似心衰患者早期启动疾病修饰治疗的获益

Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.
PubMed 文献 · Eur Heart J · 2026-01-01

基于CPRD的队列研究纳入社区NT-proBNP≥400 pg/mL且无既往心衰史的患者,随访12个月。在已有非心衰适应症(2型糖尿病、慢性肾脏病或难治性高血压)的患者中,若在NT-proBNP测量时启动SGLT2i和MRA,估计每1000例治疗可避免84例心衰住院或死亡,NNT为12(95%CI 11-14)。

要点

  • 社区NT-proBNP≥400 pg/mL提示疑似心衰,12个月内32%记录心衰诊断。
  • 已有非心衰适应症者早期联用SGLT2i和MRA,NNT=12(95%CI 11-14)。
  • 早期治疗可在等待诊断性超声心动图期间减少不良结局。

核心结论

  • 社区疑似心衰且NT-proBNP升高者,若已有SGLT2i或MRA的非心衰适应症,早期启动两者可能减少12个月心衰住院或死亡。

研究设计与样本

  • 队列研究,使用CPRD链接的初级和二级医疗数据,时间2015年1月1日至2023年3月31日。
  • 纳入无既往心衰史且未处方SGLT2i或MRA、社区NT-proBNP≥400 pg/mL的患者,随访12个月。
  • 在NT-proBNP测量时,对已有非心衰适应症(2型糖尿病、慢性肾脏病或难治性高血压)者,使用已确诊心衰患者随机安慰剂对照试验荟萃分析的治疗效应估计来建模。

主要发现

  • 74 945例记录NT-proBNP≥400 pg/mL,其中24 082例(32%)在12个月内记录心衰诊断。
  • 24 082例中15 398例(64%)为门诊诊断,8684例(36%)为心衰住院期间诊断。
  • 若在NT-proBNP升高时对已有非心衰适应症者同时启动SGLT2i和MRA,估计每1000例治疗可避免84例12个月心衰住院或死亡,NNT为12(95%CI 11-14)。

关键数值与推荐

  • 社区NT-proBNP≥400 pg/mL作为疑似心衰的检测阈值。
  • 非心衰相关适应症包括2型糖尿病、慢性肾脏病或难治性高血压。
  • 主要结局为随访期间无 documented 心衰诊断且未行超声心动图者的复合终点:以心衰住院作为首次记录的心衰诊断事件或全因死亡。

临床怎么用

  • 对社区NT-proBNP≥400 pg/mL且已有SGLT2i或MRA非心衰适应症者,可考虑在等待超声心动图前早期启动SGLT2i和MRA。
  • 该策略可能减少早期心衰住院或死亡,NNT为12(95%CI 11-14)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The initiation of heart failure (HF) therapies at the time of detection of an elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) level in community-based patients with suspected HF may reduce the risk of early adverse outcomes. The aim of this analysis was to estimate the potential benefit of the early initiation of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and/or mineralocorticoid receptor antagonist (MRA) in patients with suspected HF and a pre-existing non-HF-related indication for treatment. METHODS: A cohort study was performed from 1 January 2015 to 31 March 2023 using linked primary and secondary care data from the Clinical Practice Research Datalink (CPRD). Patients without a history of HF and who were not prescribed an SGLT2i or MRA were followed up for 12 months following a community-measured NT-proBNP ≥ 400 pg/mL. The primary outcome was a composite of a HF hospitalization as the first recorded HF diagnostic event or death from any cause in patients without a documented HF diagnosis during follow-up and who did not undergo echocardiography. The effect of the initiation of treatment with an SGLT2i, MRA, or both (effective treatments for HF regardless of ejection fraction) was modelled at the time of NT-proBNP measurement in patients with a pre-existing non-HF-related indication for these drugs (Type 2 diabetes, chronic kidney disease, or resistant hypertension) using treatment effect estimates from meta-analyses of randomized placebo-controlled trials in patients with established HF. RESULTS: An NT-proBNP ≥ 400 pg/mL was recorded in 74 945, 24 082 (32%) of whom had a HF diagnosis recorded within 12 months, 15 398 (64%) as an outpatient and 8684 (36%) during a HF hospitalization. If both an SGLT2i and MRA were commenced at the measurement of an elevated NT-proBNP in those with a pre-existing non-HF-related indication, we estimated that for every 1000 patients treated, 84 would avoid either a HF hospitalization or death at 12 months, equating to a number needed to treat of 12 (95% confidence interval 11-14). CONCLUSIONS: In community-based patients with suspected HF and elevated NT-proBNP, the early initiation of an SGLT2i and an MRA in patients with a pre-existing non-HF-related indication for treatment may reduce the risk of early adverse outcomes whilst awaiting diagnostic echocardiography. These findings suggest a simple clinical strategy with potentially large public health benefits.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Docherty KF, Heywood B, Bayes-Genis A, et al. Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure. Eur Heart J. 2026. PMID: 40879671. doi:10.1093/eurheartj/ehaf675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。